News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Ruben Mesa: Excited to participate in “Celebrate Research” across Advocate Health
Ruben Mesa/LinkedIn
Feb 4, 2025, 17:17

Ruben Mesa: Excited to participate in “Celebrate Research” across Advocate Health

Ruben Mesa, President of Atrium Health Levine Cancer Institute, shared a post on LinkedIn:

“So excited to participate in “Celebrate Research” across Advocate Health on March 13th “Going Beyond Science: The Importance of Oncology Research for Patients and Communities” at Advocate Health Care Lutheran General Hospital! Join me at the event in your Advocate Health Center Wake Forest University School of Medicine.”

cancer Cancer research OncoDaily Oncology Ruben Mesa
Special Coverage
Drugs
Feb 4, 2025, 17:18
Multimodal approaches combining IO and IO-based therapies for HCC - Digestive Cancers Europe
Blog
Feb 4, 2025, 17:17
Ruben Mesa: Excited to participate in “Celebrate Research” across Advocate Health
Blog
Feb 4, 2025, 17:16
Susana Banerjee: Thanks to the 64 participants from 31 countries at the ESMO Resilience Task Force workshop
Science
Feb 4, 2025, 17:11
Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer
Societies
Feb 4, 2025, 17:10
ESMO is joining the 156th WHO Executive Board Meeting
Blog
Feb 4, 2025, 17:07
Run for the Alliance - Colorectal Cancer Alliance
Science
Feb 4, 2025, 17:07
Giovanni Marchegiani: Can we make a soft pancreas harder to reduce POPF?
Societies
Feb 4, 2025, 17:05
Rallying support to overcome the hurdles of cancer care costs - Canadian Cancer Society
Insight
Feb 4, 2025, 17:04
Hung Trinh: Oncolytic virus and CAR-T cell therapy in solid tumors
Science
Feb 4, 2025, 17:03
Michael Hofman: 18F-CETO for primary aldosteronism
Blog
Feb 4, 2025, 17:02
Axel S. Merseburger: When would you consider HR clinically meaningful in HRR allcomer population?
Science
Feb 4, 2025, 17:00
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors by Nikhil Vojjala et al.